6:20 PM
 | 
Oct 23, 2012
 |  BC Extra  |  Clinical News

SARcode reports Phase III data for dry eye treatment

SARcode Bioscience Inc. (Brisbane, Calif.) said twice-daily lifitegrast met the co-primary endpoint of improving inferior corneal staining scores from baseline to week 12 vs. placebo in the Phase III OPUS-1 trial to treat dry eye disease (p=0.0007). Lifitegrast missed the co-primary endpoint of improving visual-related function...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >